| Literature DB >> 29407948 |
Sara Guariento1, Michele Tonelli2, Stefano Espinoza3, Andrey S Gerasimov4, Raul R Gainetdinov5, Elena Cichero6.
Abstract
The design of novel chemical classes acting towards several G-protein-coupled receptors (GPCRs) represents a leading strategy in drug discovery, aimed at deriving effective and safe candidates for further assessment. During the last years, TAAR1 arose as a promising druggable target in medicinal chemistry, being of interest in the treatment of several pathologies, such as neuropsychiatric disorders, type 2 diabetes and obesity. Nevertheless, the limited number of known potent and selective ligands and the species-specificity responsiveness exhibited by those derivatives nowadays available make the discovery of novel compounds a challenging task. Herein, we discuss the development of two quantitative-structure activity relationship (QSAR) models around the agonism ability experienced by different chemo-types toward murine and human TAAR1 (m/hTAAR1) with the aim at deciphering some clues involved in their species-specificity responsiveness. Qualitatively, these information were evaluated guiding for the synthesis of novel ligands, which proved to feature selective agonism ability with respect to the mTAAR1 and hTAAR1 orthologues.Entities:
Keywords: Agonists; Biguanide; Docking; QSAR; TAAR1; Thyronamines
Mesh:
Substances:
Year: 2018 PMID: 29407948 DOI: 10.1016/j.ejmech.2018.01.059
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514